Literature DB >> 33549442

Circulating pro-neurotensin levels predict bodyweight gain and metabolic alterations in children.

Ilaria Barchetta1, Laura Bertoccini1, Federica Sentinelli2, Diego Bailetti2, Giacomo Marini3, Flavia Agata Cimini1, Valentina Ceccarelli1, Joachim Struck4, Janin Schulte4, Sandro Loche5, Efisio Cossu3, Olle Melander6, Maria G Cavallo1, Marco G Baroni7.   

Abstract

BACKGROUND AND AIMS: Neurotensin (NT) is an intestinal peptide released after fat ingestion, which regulates appetite and facilitates lipid absorption. Elevated plasma levels of its stable precursor pro-neurotensin (pro-NT) are associated with type 2 diabetes, obesity and cardiovascular mortality in adult populations; no data on pro-NT and metabolic disease are available in children. Aim of the study was to evaluate plasma pro-NT in relation to the presence of obesity in children, and to test if high pro-NT associates with the development of metabolic impairment later in life. METHODS AND
RESULTS: For this longitudinal retrospective study, we studied 151 overweight/obese children undergoing metabolic evaluations at University of Cagliari, Italy. Pro-NT was also assessed in 46 normal-weight, age-, sex-comparable normal-weight children, selected as a reference group. At the baseline, pro-NT was comparable between overweight/obese and normal-weight children and correlated positively with age (p < 0.001), triglycerides (p < 0.001) and inversely with HDL levels (p = 0.008). Plasma pro-NT associated with high triglycerides with OR = 5.9 (95%CI: 1.24-28.1; p = 0.026) after adjustment for multiple confounders. At the 6.5-year follow-up, high basal pro-NT associated with impaired β-cell function to compensate for insulin-resistance (disposition index: r = -0.19, p = 0.035) and predicted bodyweight increase, as indicated by percentage change of standard deviation score BMI (median(95%CI) = +20.8(+4.9-+27.5)% in the highest tertile), independently from age, sex, triglycerides and insulin-resistance (standardized β = 0.24; p = 0.036).
CONCLUSIONS: Elevated pro-NT levels in children are significantly associated with weight gain later in life and may represent a marker of susceptibility to metabolic impairment in presence of obesity.
Copyright © 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Disposition index; Insulin-resistance; Neurotensin; Obesity; Triglycerides; pro-NT

Year:  2020        PMID: 33549442     DOI: 10.1016/j.numecd.2020.11.025

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  4 in total

1.  High pro-neurotensin levels in individuals with type 1 diabetes associate with the development of cardiovascular risk factors at follow-up.

Authors:  Flavia Agata Cimini; Ilaria Barchetta; Laura Bertoccini; Valentina Ceccarelli; Marco Giorgio Baroni; Olle Melander; Maria Gisella Cavallo
Journal:  Acta Diabetol       Date:  2021-08-29       Impact factor: 4.280

Review 2.  New Insights in the Control of Fat Homeostasis: The Role of Neurotensin.

Authors:  Ilaria Barchetta; Marco Giorgio Baroni; Olle Melander; Maria Gisella Cavallo
Journal:  Int J Mol Sci       Date:  2022-02-17       Impact factor: 6.208

3.  Circulating Levels of Pro-Neurotensin and Its Relationship with Nonalcoholic Steatohepatitis and Hepatic Lipid Metabolism.

Authors:  Beatriz Villar; Laia Bertran; Carmen Aguilar; Jessica Binetti; Salomé Martínez; Fàtima Sabench; Monica Real; David Riesco; Marta París; Daniel Del Castillo; Cristóbal Richart; Teresa Auguet
Journal:  Metabolites       Date:  2021-06-10

4.  Effect of Monoclonal Antibody Blockade of Long Fragment Neurotensin on Weight Loss, Behavior, and Metabolic Traits After High-Fat Diet Induced Obesity.

Authors:  Zherui Wu; Nicolas Stadler; Amazigh Abbaci; Jin Liu; Agnès Boullier; Nicolas Marie; Olivier Biondi; Marthe Moldes; Romain Morichon; Bruno Feve; Olle Melander; Patricia Forgez
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-08       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.